3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Colorectal Neoplasms
3
Small Cell Lung Carcinoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Melanoma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Chordoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Advanced Solid Malignancies
1
Advanced Rare Malignant Solid Neoplasm
1
Advanced Liver Cancers
1
Interventions
Cisplatin
26
Paclitaxel
21
pembrolizumab
15
Radiotherapy
13
Carboplatin
13
tislelizumab
12
Fluorouracil
12
Drug Therapy
11
Irinotecan
9
toripalimab
8
Esophagectomy
8
Oxaliplatin
6
Nivolumab
6
Capecitabine
6
Neoadjuvant Therapy
5
Leucovorin
5
Docetaxel
5
lenvatinib
4
camrelizumab
4
Taxes
4
Radiation
4
Levoleucovorin
4
Immune Checkpoint Inhibitors
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
spartalizumab
3
sintilimab
3
apatinib
3
Itraconazole
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Tiragolumab
×
1 year
×
Clear all
NCT04543617
2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3
Active not recruiting
760 enrolled